Literature DB >> 19266253

Nitrosative stress, protein tyrosine nitration, PARP activation and NAD depletion in the kidneys of rats after single dose of cyclophosphamide.

Premila Abraham1, Suganthy Rabi2.   

Abstract

OBJECTIVES: Cyclophosphamide (CP) and its structural analogue ifosfamide are highly effective cytostatic drugs. While both cyclophosphamide and ifosfamide have severe urotoxic side effects, only ifosfamide is thought to be nephrotoxic. The nephrotoxicity of CP in generally overlooked because of normal plasma creatinine levels. Therefore, little information is available regarding the pathogenic mechanism of renal damage by CP. In the present study, we investigated the role of nitrosative stress in CP-induced renal damage.
METHODS: The experimental rats received a single i.p. of 150 mg/kg body weight CP in saline and were killed 6 h or 16 h later. The control rats received saline. The kidneys were used for histological and biochemical analysis. Nitrotyrosine and poly (ADP-ribose) polymerase (PARP) were localized immunohistochemically as indicators of protein nitration and DNA damage, respectively. Nitrite, NAD and superoxide dismutase (SOD) activity were assayed in the kidney homogenates.
RESULTS: The nitrite level in the kidneys of CP-treated rats was elevated twofold. The kidneys of CP-treated rats stained strongly for nitrotyrosine as well as for PARP. Significant decrease in oxidized NAD levels was also observed in the kidneys of CP-treated rats. The activity of the peroxynitrite sensitive enzyme SOD was significantly reduced in the kidneys of CP-treated rats.
CONCLUSION: The results of the present study reveal that nitrosative stress may play an important role in CP-induced renal damage. It is suggested that protein nitration, PARP activation and NAD +/- depletion may play a critical role in the pathogenesis of cyclophosphamide induced renal damage.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19266253     DOI: 10.1007/s10157-009-0160-z

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  36 in total

Review 1.  An overview of cyclophosphamide and ifosfamide pharmacology.

Authors:  R A Fleming
Journal:  Pharmacotherapy       Date:  1997 Sep-Oct       Impact factor: 4.705

2.  The effects of anticancer drugs on levels of nitric oxide and adrenomedullin.

Authors:  Elif Güler; Ayşe Balat; Mustafa Cekmen; Metin Kilinç; Ercan Sivasli; Muhittin Yürekli; Can Duman
Journal:  Turk J Pediatr       Date:  2006 Jul-Sep       Impact factor: 0.552

Review 3.  Metabolism and pharmacokinetics of oxazaphosphorines.

Authors:  A V Boddy; S M Yule
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

Review 4.  Nitric oxide in renal health and disease.

Authors:  B C Kone
Journal:  Am J Kidney Dis       Date:  1997-09       Impact factor: 8.860

5.  Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles.

Authors:  P Roy; L J Yu; C L Crespi; D J Waxman
Journal:  Drug Metab Dispos       Date:  1999-06       Impact factor: 3.922

6.  Peroxynitrite may be involved in bladder damage caused by cyclophosphamide in rats.

Authors:  Ahmet Korkmaz; Sukru Oter; Serdar Sadir; Omer Coskun; Turgut Topal; Mehmet Ozler; Hayati Bilgic
Journal:  J Urol       Date:  2005-05       Impact factor: 7.450

7.  Role of peroxynitrite and activation of poly (ADP-ribose) synthase in the vascular failure induced by zymosan-activated plasma.

Authors:  S Cuzzocrea; B Zingarelli; M O'Connor; A L Salzman; A P Caputi; C Szabó
Journal:  Br J Pharmacol       Date:  1997-10       Impact factor: 8.739

8.  Characterization of the capsaicin-sensitive component of cyclophosphamide-induced inflammation in the rat urinary bladder.

Authors:  A Ahluwalia; C A Maggi; P Santicioli; A Lecci; S Giuliani
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

Review 9.  [Cyclophosphamide in the therapy of rheumatoid arthritis and its complications].

Authors:  Jakub Trefler; Ewa Matyska-Piekarska; Jan K Łacki
Journal:  Pol Merkur Lekarski       Date:  2007-06

10.  Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture.

Authors:  M Mohrmann; S Ansorge; U Schmich; B Schönfeld; M Brandis
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

View more
  5 in total

1.  Progression of cyclophosphamide-induced acute renal metabolic damage in carnitine-depleted rat model.

Authors:  Mohamed M Sayed-Ahmed
Journal:  Clin Exp Nephrol       Date:  2010-07-23       Impact factor: 2.801

2.  Carnitine deficiency and oxidative stress provoke cardiotoxicity in an ifosfamide-induced Fanconi Syndrome rat model.

Authors:  Mohamed M Sayed-Ahmed; Amal Q Darweesh; Amal J Fatani
Journal:  Oxid Med Cell Longev       Date:  2010 Jul-Aug       Impact factor: 6.543

3.  Inhibition of gene expression of organic cation/carnitine transporter and antioxidant enzymes in oxazaphosphorines-induced acute cardiomyopathic rat models.

Authors:  Mohamed M Sayed-Ahmed; Meshan Lafi Aldelemy; Mohamed M Hafez; Othman A Al-Shabanah
Journal:  Oxid Med Cell Longev       Date:  2012-05-30       Impact factor: 6.543

Review 4.  Potential Protective Effects of Antioxidants against Cyclophosphamide-Induced Nephrotoxicity.

Authors:  Muluken Altaye Ayza; Kaleab Alemayehu Zewdie; Elias Fitsum Yigzaw; Solomon Gashaw Ayele; Bekalu Amare Tesfaye; Gebrehiwot Gebremedhin Tafere; Muzey Gebreyohannes Abrha
Journal:  Int J Nephrol       Date:  2022-04-16

5.  Effect of diethyldithiocarbamate in cyclophosphamide-induced nephrotoxicity: Immunohistochemical study of superoxide dismutase 1 in rat.

Authors:  Vaibhav G Sheth; Umashanker Navik; Krishna Prahlad Maremanda; Gopabandhu Jena
Journal:  Indian J Pharmacol       Date:  2018 Jan-Feb       Impact factor: 1.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.